MFL-P chemotherapy for pretreated metastatic breast cancer patients: A regimen with triple biochemical modulation by MTX-5FU, LV-5FU and 5FU-CDDP

Breast Cancer

Volumn 6, Issue 3, 1999, Pages 187-191

  Kan, Norimichi ^a   Honda, Goro ^b  

^a Rakuyo Hospital   (Japan)

^b SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Advanced breast cancer; Cisplatin; Leucovorin; Methotrexate

Indexed keywords

EID: 0001369603     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967166     Document Type: Article

References (22)

1. Bruckner HW, Cohen J: MTX/5-FU trials in gastrointestinal and other cancer. Semin Oncol 10(suppl 2):32-39, 1983. (Pubitemid 13049478)
2. Gohdmann JJ, Macdonald JS: Chemotherapy of gastric cancer. Cancer Invest 7:39-52, 1989. (Pubitemid 19192624)
3. Kan N, Okino T, Inoue K, et al: Evaluation of outpatient cisplatin for patients with advanced or recurrent gastric cancer; Combination with immunotherapy or other anti-cancer agents. Kiso to Rinsyou 28:833-841, 1994 (in Japanese with English abstract).
4. Japanese Society for Cancer Therapy: General Rules for Reporting on Clinical Oncology, 1st ed, Kanehara, Tokyo, pp1-101, 1991.
5. Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, 2th ed, Kanehara, Tokyo, pp1-68, 1996.
6. Scanlon KJ, Newman EM, Lu Y, et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923-8925, 1986. (Pubitemid 17223512)
7. Nashimoto A, Sasaki J, Akai S, et al: Ambulatory combination chemotherapy with cisplatin and 5-fluorouracil for advanced gastric cancer patients. J Jpn Soc Cancer Ther 27:654-664, 1992.
8. Creagan ET, Richardson RL, Kavach JS: Pilot study of a continuous five-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer. J Clin Oncol 6:1197-1201, 1988.
9. Lokich JJ, Ahlgren JD, Cantrell J, et al: A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma; A Mid-Atlantic Oncology Program study. Cancer 67:14-19, 1991.
10. Suga S, Kimura K, Nagai H, et al: An evaluation of gastric cancers given UFT/CDDP chemotherapy. Gan no Rinsyou 37:929-939, 1991 (in Japanese with English abstract).
11. Klaassen U, Wilke H, Weyhofen R, et al: Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Anti-Cancer Drugs 9:203-207, 1998. (Pubitemid 28186517)
12. Sasaki T: Sequential methotrexate and 5-fluorouracil. Jpn J Cancer Chemother 23:1907-1910, 1996.
13. Oura S, Sakura T, Yoshimura G, et al: Result of biochemical modulation therapy of 5-FU with low dose cisplatin for anthracycline resistant breast carcinoma. J Jpn Soc Cancer Ther 31:957-964, 1996. (Pubitemid 26384946)
14. Alonso V, Santander C, Florian J, et al: Phase II trial of oral tegafur and folinic acid with mitoxantrone as first-line regimen in patients with metastatic breast cancer. Tumori 82:61-64, 1996. (Pubitemid 26147213)
15. Haaz MC, Fischel JL, Forment P, et al: Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase. Cancer Chemother Pharmacol 38:52-58, 1996. (Pubitemid 26097551)
16. Okino T, Kan N, Satoh K, et al: Therapeutic effect of sequential chemotherapy using methotrexate, 5-FU, leucovorin and cisplatin (MFLP) against advanced and/or recurrent gastric cancer. In: Siewert JR, Roder JD eds, Progress in Gastric Cancer Research 1997, Monduzzi Editore SpA, Bologna, pp1819-1823, 1997.
17. Platesi G, Gianni L, Manzotti C, et al: Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 21:237-240, 1988.
18. Kuroki M, Nakano S, Mitsugi K, et al: In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line. Cancer Chemother Pharmacol 29:273-276, 1992.
19. Furukawa S, Yoshida T, Tukuda M, et al: Experimental study on combination chemotherapy with platinum compounds and 5-fluorouracil. Jpn J Cancer Chemother 16 (part-I):419-422, 1989.
20. Esaki T, Nakano S, Matsumoto N, et al: Schedule-dependent reversion by 5-fluorouracil in a newly established cisplatin-resistent HST-1 human squamous carcinoma cell line. Int J Cancer 65:479-484, 1996. (Pubitemid 26083256)
21. Nakano S, Niho Y: 5-Fluorouracil and cisplatin sequential chemotherapy; Mechanism of action and clinical application in advanced, unresectable non-small cell lung cancer. Intern Med 34:288-291, 1995.
22. Bruckner HW, Chesser MR, Wong H, et al: Folate biochemical modulation regimen for the treatment of gastric cancer. J Clin Gastroenterol 13:384-389, 1991.